Deliver a solid set

“We deliver a solid set of full year results despite the COVID-19 outbreak. Our priorities have been clear throughout the pandemic; 

we need to keep our employees safe, while continuing to serve our customers. So far, we have succeeded in mitigating the pandemic, while maintaining business continuity,” 

 “Our full year results were negatively impacted by the cancellation of elective procedures in our Interventional Urology business as well as a negative impact from the pandemic 

on our Wound & Skin Care business in China and on our Chronic Care business in the UK. We continue to adapt our business to the challenging situation, and we are encouraged 

by the largely stable underlying growth in the US and in our Emerging Markets. 

In the fourth quarter of the 2019/20 financial year, organic growth rates by business area were 3% in Ostomy Care, 4% in Continence Care, 0% in Interventional Urology, and -3% in Wound & Skin Care.

The fourth quarter was negatively impacted by flat growth in several countries in Europe due to limited growth in new patients due to COVID-19, especially in the UK Chronic Care business. 

Wound & Skin Care was adversely affected by a decline in hospital procedures in China and the wider Emerging markets region due to COVID-19. On a positive note, 

the newly launched Biatain Fiber wound dressing is beginning to contribute to growth in Europe.

COVID-19 pandemic

Coloplast continues to monitor developments closely across all markets and business areas and continues to take all necessary precautionary measures to comply with and support local, national, and global guidelines from healthcare authorities.   

The company’s global manufacturing sites are operating at normal capacity in terms of production and supply chain, and the company continues to fully meet demand.